These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18068281)

  • 1. Supportive care, growth factors, and new therapies in myelodysplastic syndromes.
    Hellström-Lindberg E; Malcovati L
    Blood Rev; 2008 Mar; 22(2):75-91. PubMed ID: 18068281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes.
    Hellström-Lindberg E; Malcovati L
    Semin Hematol; 2008 Jan; 45(1):14-22. PubMed ID: 18179965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
    Bowen DT
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S16-23. PubMed ID: 16085013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.
    Cazzola M
    Int J Hematol; 2000 Aug; 72(2):134-8. PubMed ID: 11039660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating novel agents in the treatment of myelodysplastic syndromes.
    Anargyrou K; Vassilakopoulos TP; Angelopoulou MK; Terpos E
    Leuk Res; 2010 Jan; 34(1):6-17. PubMed ID: 19656566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS).
    List AF
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S31-5. PubMed ID: 16085015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life.
    Balducci L
    Cancer; 2006 May; 106(10):2087-94. PubMed ID: 16607649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational research in myelodysplastic syndromes.
    Raza A; Qawi H; Mehdi M; Mumtaz M; Galili N
    Rev Clin Exp Hematol; 2004 Dec; 8(2):E2. PubMed ID: 16027100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies in myelodysplastic syndrome.
    Melchert M; List A
    Semin Hematol; 2008 Jan; 45(1):31-8. PubMed ID: 18179967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing patients with low-risk MDS.
    Sekeres M; Cosgrove D; Falco A
    Clin Adv Hematol Oncol; 2006 Jul; 4(7 Suppl 16):1-10; quiz 11-2. PubMed ID: 17139240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel agents for the management of myelodysplastic syndromes.
    Meletis J; Viniou N; Terpos E
    Med Sci Monit; 2006 Sep; 12(9):RA194-206. PubMed ID: 16940944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic growth factors in the treatment of acquired bone marrow failure states.
    Marsh JC; Ganser A; Stadler M
    Semin Hematol; 2007 Jul; 44(3):138-47. PubMed ID: 17631178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapeutic agents for the treatment of myelodysplastic syndromes.
    Cheson BD; Zwiebel JA; Dancey J; Murgo A
    Semin Oncol; 2000 Oct; 27(5):560-77. PubMed ID: 11049023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
    Cazzola M
    Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
    Leone G; Teofili L; Voso MT; Lübbert M
    Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in supportive care of myelodysplastic syndromes.
    Gordon MS
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):21-4. PubMed ID: 10530713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of adult myelodysplastic syndromes.
    Hellström-Lindberg E
    Int J Hematol; 1999 Oct; 70(3):141-54. PubMed ID: 10561906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.